产品
编 号：F744931
分子式：C23H28N2O3
分子量：380.48
分子式：C23H28N2O3
分子量：380.48
产品类型
规格
价格
是否有货
结构图
CAS No: 1418093-75-0
产品详情
生物活性：
IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research.
体内研究：
IMMH001 is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo.IMMH001 suppresses both Th1 cell (IL-1β, IL-18, and IP10) and Th2 cell (IL-5)-mediated disease reactions in damaged joints.IMMH001 (0.3-2.4 mg/kg, Orally; twice a week, for 28 days, AA rats; for 30 days, CIA rats) relieves the damage of AA (adjuvant-induced arthritis) and CIA (collagen-induced arthritis) rats’ joints.
IMMH001, also called SYL930, is an orally active, potent and selective S1P1 (sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research.
体内研究：
IMMH001 is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo.IMMH001 suppresses both Th1 cell (IL-1β, IL-18, and IP10) and Th2 cell (IL-5)-mediated disease reactions in damaged joints.IMMH001 (0.3-2.4 mg/kg, Orally; twice a week, for 28 days, AA rats; for 30 days, CIA rats) relieves the damage of AA (adjuvant-induced arthritis) and CIA (collagen-induced arthritis) rats’ joints.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备